Anorexia nervosa (AN) is a complex and severe eating disorder that has long been considered a psychiatric condition driven by distorted body image and maladaptive eating behaviors. No effective ...

Astrazeneca plc has added a dual PDE3/4 inhibitor candidate to its chronic obstructive pulmonary disease (COPD) portfolio via ...

The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around tau. Sunday’s plenary speaker Ryan Watts, ...

South Korea is moving ahead with its biggest reform of drug review and pricing in more than a decade, reflecting a wider shift across Asian markets to reward innovation and tighten controls on ...

A federal jury was wrong when it determined that Astrazeneca plc should pay Wyeth, a Pfizer Inc. unit, $107.5 million in damages for infringing two cancer patents, the U.S. Court of Appeals for the ...

The U.K. is setting up a nationwide registry of people with dementia, who will be pre-screened and consented, to speed up recruitment to clinical trials and collect real-world evidence of ...

The clinically proven promise of an alopecia drug, without the risks of black box-bearing JAK inhibitors yet with powerful ...

Zeta Surgical Inc. received U.S. FDA 510(k) clearance for its transcranial magnetic stimulation (TMS) robotic system which is designed to support precise and repeatable TMS therapy for patients with ...

Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: C2N, Moderna, Pegbio, Precisio Biotix, Rani, Roche, Tibaray, Xvivo.

Mindrank AI Ltd. completed a $52 million series B round to advance MDR-001, its AI-discovered oral small-molecule GLP-1 receptor agonist, which is in phase III trials for obesity in China.

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are ...